Literature DB >> 6154425

Detection of circulating antibodies in cutaneous leishmaniasis by enzyme-linked immunosorbent assay (ELISA).

J Roffi, J P Dedet, P Desjeux, M T Garré.   

Abstract

An immunoenzymatic diagnostic technique applicable to cutaneous leishmaniasis is described. The antigen used (Leishmania tropica major) was equally useful in diagnosing visceral and mucocutaneous forms of the disease. The criteria for positivity were defined by using groups of negative controls, and the specificity of the reaction was evaluated by using sera from patients with various diseases. Among these, sera from patients with lepromatous leprosy, tuberculosis, or African trypanosomiasis strongly cross-reacted with leishmania antigen. Examining serial dilutions of the sera facilitated the interpretation of the results and eliminated a significant percentage of false positives.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6154425     DOI: 10.4269/ajtmh.1980.29.183

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  9 in total

1.  Enzyme-linked immunosorbent assay based on soluble promastigote antigen detects immunoglobulin M (IgM) and IgG antibodies in sera from cases of visceral and cutaneous leishmaniasis.

Authors:  Jeffrey R Ryan; Anthony M Smithyman; G-Halli Rajasekariah; Lisa Hochberg; John M Stiteler; Samuel K Martin
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Immunodiagnosis in parasitic disease.

Authors:  J K Cruickshank; C Mackenzie
Journal:  Br Med J (Clin Res Ed)       Date:  1981-11-21

3.  The six diseases of WHO. Leishmaniasis.

Authors:  M L Chance
Journal:  Br Med J (Clin Res Ed)       Date:  1981-11-07

4.  Detection of Leishmania donovani infection using magnetic beads-based serum peptide profiling by MALDI-TOF MS in mice model.

Authors:  Lixia Li; Jiping Li; Hongtao Jin; Limin Shang; Bo Li; Feng Wei; Quan Liu
Journal:  Parasitol Res       Date:  2011-08-18       Impact factor: 2.289

5.  Epitope mapping of the HSP83.1 protein of Leishmania braziliensis discloses novel targets for immunodiagnosis of tegumentary and visceral clinical forms of leishmaniasis.

Authors:  Daniel Menezes-Souza; Tiago Antônio de Oliveira Mendes; Matheus de Souza Gomes; João Luís Reis-Cunha; Ronaldo Alves Pinto Nagem; Cláudia Martins Carneiro; Eduardo Antônio Ferraz Coelho; Lúcia Maria da Cunha Galvão; Ricardo Toshio Fujiwara; Daniella Castanheira Bartholomeu
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

6.  Comparative study of amplification systems in immunoenzyme assays for the diagnosis of American tegumentary leishmaniasis.

Authors:  Lílian Dias Nascimento; Sonia Regina Lambert Passos; Eliame Mouta-Confort; Marta de Almeida Santiago; Andreia Silva Alves; Maria de Fátima Madeira; Armando de Oliveira Schubach; Mauro Célio de Almeida Marzochi
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

7.  Rapid identification of Leishmania species by specific hybridization of kinetoplast DNA in cutaneous lesions.

Authors:  D F Wirth; D M Pratt
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

8.  Mapping B-cell epitopes for the peroxidoxin of Leishmania (Viannia) braziliensis and its potential for the clinical diagnosis of tegumentary and visceral leishmaniasis.

Authors:  Daniel Menezes-Souza; Tiago Antônio de Oliveira Mendes; Ronaldo Alves Pinto Nagem; Thaís Teodoro de Oliveira Santos; Ana Luíza Teixeira Silva; Marcelo Matos Santoro; Silvio Fernando Guimarães de Carvalho; Eduardo Antônio Ferraz Coelho; Daniella Castanheira Bartholomeu; Ricardo Toshio Fujiwara
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

9.  Towards a more precise serological diagnosis of human tegumentary leishmaniasis using Leishmania recombinant proteins.

Authors:  Ana Paula Souza; Manuel Soto; Jackson M L Costa; Viviane S Boaventura; Camila I de Oliveira; Juqueline R Cristal; Manoel Barral-Netto; Aldina Barral
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.